Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

ABSTRACT: RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

PROVIDER: PRJNA602869 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602860 | ENA

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

| PRJNA602858 | ENA

RNA-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144131 | GEO

In Situ on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144126 | GEO

H3K27me3 and H3K4me3 ChIP-seq on DMSO and EPZ6438 treated CD34+ HSPCs

Project description:The overall goal is to understand how does the DNA methylation Canyon interactions in CD34+ HSPCs can be impacted by the inhibition of EZH2

2020-01-24 | GSE144124 | GEO

DARTseq identifies m6A targets in human CD34+ HSPCs

Project description:The goal of this study is to identify m6A targets in human CD34+ HSPCs with or without STM2457 treatment using DARTseq. Purified human CD34+ HSPC cells were transduced with APOBEC-YTH or empty vector control (MIG). 24hr post infection, CD34+ cells were treated with STM2457 at a concentration of 20µM for 2 days. GFP+ cells were sorted the next day. 3 replicates were performed.

2023-12-07 | GSE231861 | GEO

RNA-seq of healthy CD34+ HSPCs after co-culture with myelodyplastic syndrome patient-derived mesenchymal stromal cells

Project description:Cytopenia in at least one of the hematopoietic lineages (RBCs, WBCs or platelets) is a hallmark feature of MDS, indicating the lack of ability to support HSPC proliferation and the retention of their multilineage potential in the bone marrow. Here, wel investigate MDS-MSCs (with and without 5-azacitidine pre-treatment) as feeder layers for healthy CD34+ HSPCs. We performed RNA sequencing of co-cultured CD34+ HSPCs to compare their transcriptomic signatures after exposure to treated vs untreated MDS-MSCs.

2019-09-30 | GSE119916 | GEO

Transcriptome data of uncultured and HGFs along with 0.1% DMSO or LY plus Rapa or SR1-treated hUCB CD34+ cells

Project description:mRNA profiling of uncultured and HGFs along with 0.1% DMSO (HGFs) or LY plus Rapa (LR) or SR1-treated hUCB CD34+ cells

2020-06-08 | GSE151964 | GEO

Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

Project description:Transcriptome of CBX7 and CBX8 overexpressing CD34+ HSPCs

| PRJEB22831 | ENA

Expression data from untreated and valproic acid (VPA) treated CD34+ Hematopoietic Stem Cells (HSCs)

Project description:Histone deacetylase (HDAC) inhibitors are widely utilized in hematopoietic malignance therapy; nevertheless, little is currently known concerning their effects on normal myelopoiesis. In order to investigate a putative interference of HDAC inhibitors in myeloid commitment of hematopoietic stem/progenitor cells (HSPCs) we treated CD34+ cells with valproic acid (VPA). Moreover, we investigate changes in gene expression induced by VPA treatment on HSPCs, by means of microarray analysis in VPA treated and untreated (CTR) CD34+ cells. VPA treatment induced H4 histone acetylation in CD34+ cells and blocked them in G0-G1 phase of cell cycle. CD34 expression is maintained for a longer time in VPA treated cells, while the physiological decrease of CD34 antigen occurred in CTR cells. Moreover, VPA favored erythrocyte and megakaryocyte differentiation at the expense of granulocyte and mono-macrophage lineages, as demonstrated by immunophenotyping, morphological and clonogenic analysis. Finally, we demonstrated that VPA up-regulated master gene regulators of erythrocyte and megakaryocyte differentiation (GFI1B and MLLT3) through histone iper-acetylation of their promoters. These results indicate that VPA treatment enhances erythrocyte and megakaryocyte differentiation at the expense of granulocyte and mono-macrophage one. Microarray data provide for the first time a detailed molecular support for the biological effects promoted by VPA treatment in HSPCs.

2013-04-11 | GSE31283 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data